Abstract
This article explores various regulatory and operational strategies aimed at accelerating drug development by shortening clinical trials. The length of traditional clinical trials presents challenges in delivering timely therapies to patients, making it crucial to identify approaches that expedite the process without compromising safety or data integrity. The strategies discussed include adaptive trial designs, utilizing surrogate endpoints, leveraging real-world evidence, regulatory flexibility, streamlined protocols and procedures, and enhanced patient recruitment and enrollment. By implementing these strategies, researchers can make informed decisions, expedite data analysis, and enhance trial efficiency. The article emphasizes the importance of collaboration among stakeholders to advance the field of clinical trials and bring innovative therapies to patients more quickly
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Cancer Research & Therapy
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
